Heart failure in diabetes: effects of anti-hyperglycemic drug therapy
Studies on the cardiovascular safety of new anti-diabetic drugs have drawn attention to the problem of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). This has included one controversial study about hospitalization associated with HF in patients treated with dipeptidyl-peptidase...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN RU |
| Publicado: |
Endocrinology Research Centre
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/72cf453ff6c04bf38ea46ab8890c5153 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:72cf453ff6c04bf38ea46ab8890c5153 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:72cf453ff6c04bf38ea46ab8890c51532021-11-14T09:00:20ZHeart failure in diabetes: effects of anti-hyperglycemic drug therapy2072-03512072-037810.14341/DM2003451-57https://doaj.org/article/72cf453ff6c04bf38ea46ab8890c51532016-07-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7832https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Studies on the cardiovascular safety of new anti-diabetic drugs have drawn attention to the problem of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). This has included one controversial study about hospitalization associated with HF in patients treated with dipeptidyl-peptidase-4 inhibitors (I-DPP4) compared with placebo. Until recently, HF was not considered to be a vascular or chronic complication of diabetes. It is well known that patients with T2DM generally have a higher risk of developing HF. In addition, the mortality risk of patients with HF and diabetes is significantly higher than that among patients with HF without carbohydrate metabolism disorders. Among patients with HF, hyperglycaemia requiring anti-diabetic therapy is much more common than among patients without HF. Therefore, it is important to address this issue in terms of the pathogenesis of HF in patients with T2DM, the influence and dynamics of glycaemic control and methods to achieve glycaemic control, including the selection of various types of anti-diabetic drugs.Gagik R. GalstyanMikhail Y. GilyarovEndocrinology Research Centrearticletype 2 diabetes mellitusdpp-4 inhibitorsheart failureNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 19, Iss 3, Pp 229-236 (2016) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN RU |
| topic |
type 2 diabetes mellitus dpp-4 inhibitors heart failure Nutritional diseases. Deficiency diseases RC620-627 |
| spellingShingle |
type 2 diabetes mellitus dpp-4 inhibitors heart failure Nutritional diseases. Deficiency diseases RC620-627 Gagik R. Galstyan Mikhail Y. Gilyarov Heart failure in diabetes: effects of anti-hyperglycemic drug therapy |
| description |
Studies on the cardiovascular safety of new anti-diabetic drugs have drawn attention to the problem of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). This has included one controversial study about hospitalization associated with HF in patients treated with dipeptidyl-peptidase-4 inhibitors (I-DPP4) compared with placebo. Until recently, HF was not considered to be a vascular or chronic complication of diabetes. It is well known that patients with T2DM generally have a higher risk of developing HF. In addition, the mortality risk of patients with HF and diabetes is significantly higher than that among patients with HF without carbohydrate metabolism disorders. Among patients with HF, hyperglycaemia requiring anti-diabetic therapy is much more common than among patients without HF. Therefore, it is important to address this issue in terms of the pathogenesis of HF in patients with T2DM, the influence and dynamics of glycaemic control and methods to achieve glycaemic control, including the selection of various types of anti-diabetic drugs. |
| format |
article |
| author |
Gagik R. Galstyan Mikhail Y. Gilyarov |
| author_facet |
Gagik R. Galstyan Mikhail Y. Gilyarov |
| author_sort |
Gagik R. Galstyan |
| title |
Heart failure in diabetes: effects of anti-hyperglycemic drug therapy |
| title_short |
Heart failure in diabetes: effects of anti-hyperglycemic drug therapy |
| title_full |
Heart failure in diabetes: effects of anti-hyperglycemic drug therapy |
| title_fullStr |
Heart failure in diabetes: effects of anti-hyperglycemic drug therapy |
| title_full_unstemmed |
Heart failure in diabetes: effects of anti-hyperglycemic drug therapy |
| title_sort |
heart failure in diabetes: effects of anti-hyperglycemic drug therapy |
| publisher |
Endocrinology Research Centre |
| publishDate |
2016 |
| url |
https://doaj.org/article/72cf453ff6c04bf38ea46ab8890c5153 |
| work_keys_str_mv |
AT gagikrgalstyan heartfailureindiabeteseffectsofantihyperglycemicdrugtherapy AT mikhailygilyarov heartfailureindiabeteseffectsofantihyperglycemicdrugtherapy |
| _version_ |
1718429538799583232 |